JaLCDOI 10.18926/AMO/55210
FullText URL 71_3_259.pdf
Author Kawana, Shinichi| Yamamoto, Hiromasa| Maki, Yuho| Sugimoto, Seiichiro| Toyooka, Shinichi| Miyoshi, Shinichiro|
Abstract  Primary sternal chondrosarcoma is a rare malignant tumor that is refractory to chemotherapy and radiation. Effective therapy is radical resection of the tumor. We present two patients with primary sternal chondrosarcoma who underwent a radical resection of the lower half of the sternum and bilateral ribs, followed by reconstruction with 2 sheets of polypropylene mesh layered orthogonally. The patients have maintained almost the same pulmonary function as preoperative values, with stability of the chest wall. Although there are various ways to reconstruct the anterior chest wall, reconstruction with polypropylene mesh layered orthogonally is an easy-to-use and sufficient method.
Keywords chondrosarcoma sternum reconstruction polypropylene mesh
Amo Type Case Report
Published Date 2017-06
Publication Title Acta Medica Okayama
Volume volume71
Issue issue3
Publisher Okayama University Medical School
Start Page 259
End Page 262
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2017 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 28655947
Sort Key 12
Title Alternative Precision Medicine
Author Tomida, Shuta| Toyooka, Shinichi|
Publication Title Journal of Okayama Medical Association
Published Date 2017-04-03
Volume volume129
Issue issue1
Publisher 岡山医学会
Publisher Alternative Okayama Medical Association
Start Page 59
End Page 60
ISSN 0030-1558
NCID AN00032489
Content Type Article
language 日本語
Copyright Holders Copyright (c) 2017 岡山医学会
File Version publisher
Refereed True
DOI 10.4044/joma.129.59
Eprints Journal Name joma
References 1 ) The White House : Precision Medicine Initiative. https://www.whitehouse.gov/precision-medicine (平成29年1月閲覧) 2 ) The National Academies Press : Toward Precision Medicine : Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease (2011) . https://www.nap.edu/catalog/13284/toward-precisionmedicine-building-a-knowledgenetwork-for-biomedical-research (平成29年1 月閲覧)
JaLCDOI 10.18926/AMO/54978
FullText URL 71_2_105.pdf
Author Shinya, Takayoshi| Tanaka, Takashi| Soh, Junichi| Matsushita, Toshi| Sato, Shuhei| Toyooka, Shinichi| Yoshino, Tadashi| Miyoshi, Shinichiro| Kanazawa, Susumu|
Abstract We retrospectively assessed the dual-time-point (DTP) F-18 FDG PET/CT findings of thymic epithelial neoplasms (TENs) and investigated the diagnostic capacity of PET/CT compared to that of CT for predicting carcinoma. We calculated the ratio of the standardized uptake value of the tumor and that of the aortic arch (T/M ratio) for both the 90-min early scan and the 2-h delayed scan in 56 TEN patients. We used a multivariate logistic regression (MLR) analysis to estimate the CT features of carcinoma. We compared the diagnostic capacities of PET/CT and chest CT using receiver operating characteristic (ROC) analyses. The ROC curve revealed that the appropriate cut-off T/M ratio value for the highest accuracy was 2.39 with 75.0% accuracy. The area under the curve (AUC) was 0.855. The statistical analyses for DTP scans of 35 TEN patients demonstrated 74.3% accuracy and 0.838 AUC for the early scan versus 82.9% and 0.825 for the delayed scan. The MLR analysis indicated that mediastinal fat infiltration was a predictor of carcinoma. The ROC curve obtained for the model yielded an AUC of 0.853. Delayed scanning could improve the diagnostic capacity for carcinoma. The T/M ratio and mediastinal fat infiltration are predictive of carcinoma with moderate diagnostic accuracy.
Keywords thymic epithelial neoplasm thymic carcinoma thymoma dual-time-point PET/CT chest CT
Amo Type Original Article
Published Date 2017-04
Publication Title Acta Medica Okayama
Volume volume71
Issue issue2
Publisher Okayama University Medical School
Start Page 105
End Page 112
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2017 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 28420891
Author Morita, Mizuki| Toyooka, Shinichi|
Published Date 2016-12-01
Publication Title Journal of Okayama Medical Association
Volume volume128
Issue issue3
Content Type Article
JaLCDOI 10.18926/AMO/54816
FullText URL 70_6_507.pdf
Author Torigoe, Hidejiro| Toyooka, Shinichi| Yamamoto, Hiromasa| Soh, Junichi| Miyoshi, Shinichiro|
Abstract We present the case of a 65-year-old Japanese man diagnosed with chronic empyema (without a bronchopleural fistula) that occurred 7 months after he underwent an extrapleural pneumonectomy for right malignant pleural mesothelioma (MPM). Following thoracic drainage and irrigation for 1 month, we performed surgery by a thoracoscopic approach, in light of his general condition. We performed debridement and removal of the Gore-Tex polytetrafluoroethylene (PTFE) patch that had been used for the reconstruction of the diaphragm and the pericardium. The empyema had not relapsed when he died from recurrence of the MPM at 4 months after the thoracoscopic surgery. This patientʼs case suggests that thoracoscopic debridement and patch removal can be a therapeutic option for not only early-stage (exudative or fibrinopurulent) empyema but also late-stage (organized and chronic) empyema without a bronchopleural fistula, particularly for patients in poor general condition.
Keywords empyema chronic extrapleural pneumonectomy thoracoscopic debridement patch removal
Amo Type Case Report
Published Date 2016-12
Publication Title Acta Medica Okayama
Volume volume70
Issue issue6
Publisher Okayama University Medical School
Start Page 507
End Page 510
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 28003678
JaLCDOI 10.18926/AMO/54514
FullText URL 70_4_327.pdf
Author Watanabe, Mototsugu| Yamamoto, Hiromasa| Eikawa, Shingo| Shien, Kazuhiko| Shien, Tadahiko| Soh, Junichi| Hotta, Katsuyuki| Wada, Jun| Hinotsu, Shiro| Fujiwara, Toshiyoshi| Kiura, Katsuyuki| Doihara, Hiroyoshi| Miyoshi, Shinichiro| Udono, Heiichiro| Toyooka, Shinichi|
Abstract A study to evaluate the effect of metformin on the immune system was commenced in July 2014. Metformin is one of the most commonly prescribed drugs for type 2 diabetes, and previous studies have reported that metformin has an anti-tumor effect. The aim of this study is to evaluate the efficacy of metformin on the immune system in human cancer patients in vivo. The primary outcome parameter will be the rate change in the population of CD8+ T cells, which produce multiple cytokines.
Keywords metformin CD8+ T cells cancer immunology
Amo Type Clinical Study Protocols
Published Date 2016-08
Publication Title Acta Medica Okayama
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 327
End Page 330
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549683
Web of Sience KeyUT 000384748600018
Sort Key 10
Title Alternative Gene therapy using REIC/Dkk-3-encoding adenoviral vector for the treatment of malignant pleural mesothelioma
FullText URL 127_47.pdf
Author Toyooka, Shinichi|
Keywords 悪性胸膜中皮腫 REIC/DKK-3 遺伝子治療
Note 特集 (Feature Articles)
Publication Title 岡山医学会雑誌
Published Date 2015-04-01
Volume volume127
Issue issue1
Publisher 岡山医学会
Publisher Alternative Okayama Medical Association
Start Page 47
End Page 50
ISSN 0030-1558
NCID AN00032489
Content Type Journal Article
Related Url http://www.okayama-u.ac.jp/user/oma/
language 日本語
Copyright Holders Copyright (c) 2015 岡山医学会
File Version publisher
Refereed True
DOI 10.4044/joma.127.47
NAID 130005068349
Eprints Journal Name joma
References 1) Robinson B, Musk A, Lake R : Malignant Mesothelioma. Lancet (2005) 366, 397-408. 2) Robinson B, Lake R : Advances in Malignant Mesothelioma. N Engl J Med (2010) 353, 1591-1603. 3) Vogelzang N, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P : Phase Ⅲ Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin alone With Malignant Pleural Mesothelioma. J Clin Oncol (2003) 21, 2636-2644. 4) Sterman DH, Recio A, Vachani A, Sun J, Cheung L, DeLong P, Amin KM, Litzky LA, Wilson JM, Kaiser LR, Albelda SM : Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res (2005) 11, 7444-7453. 5) Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, Kapoor V, Sun J, Hodinka R, Brown JL, Corbley MJ, Parr M, et al. : A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions : high rate of antitumor immune responses. Clin Cancer Res (2007) 13, 4456-4466. 6) Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT, Cheng G, Sun J, Moon E, Pereira L, Wang X, Heitjan DF, et al. : A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther (2010) 18, 852-860. 7) Sterman DH, Haas A, Moon E, Recio A, Schwed D, Vachani A, Katz SI, Gillespie CT, Cheng G, Sun J, Papasavvas E, Montaner LJ, et al. : A trial of intrapleural adenoviral-mediated Interferon-alpha2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med (2011) 184, 1395-1399. 8) Mukherjee S, Haenel T, Himbeck R, Scott B, Ramshaw I, Lake RA, Harnett G, Phillips P, Morey S, Smith D, Davidson JA, Musk AW, et al. : Replication-restricted vaccinia as a cytokine gene therapy vector in cancer : persistent transgene expression despite antibody generation. Cancer Gene Ther (2000) 7, 663-670. 9) Tsuji T, Miyazaki M, Sakaguchi M, Inoue Y, Namba M : A REIC gene shows down-regulation in human immortalized cells and human tumor-derived cell lines. Biochem Biophys Res Commun (2000) 268, 20-24. 10) Tsuji T, Nozaki I, Miyazaki M, Sakaguchi M, Pu H, Hamazaki Y, Iijima O, Namba M : Antiproliferative activity of REIC/Dkk-3 and its significant down-regulation in non-small-cell lung carcinomas. Biochem Biophys Res Commun (2001) 289, 257-263. 11) Kurose K, Sakaguchi M, Nasu Y, Ebara S, Kaku H, Kariyama R, Arao Y, Miyazaki M, Tsushima T, Namba M, Kumon H, Huh NH : Decreased expression of REIC/Dkk-3 in human renal clear cell carcinoma. J Urol (2004) 171, 1314-1318. 12) Hayashi T, Asano H, Toyooka S, Tsukuda K, Soh J, Shien T, Taira N, Maki Y, Tanaka N, Doihara H, Nasu Y, Huh NH, et al. : DNA methylation status of REIC/Dkk-3 gene in human malignancies. J Cancer Res Clin Oncol (2012) 138, 799-809. 13) Abarzua F, Sakaguchi M, Takaishi M, Nasu Y, Kurose K, Ebara S, Miyazaki M, Namba M, Kumon H, Huh NH : Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase. Cancer Res (2005) 65, 9617-9622. 14) Sakaguchi M, Kataoka K, Abarzua F, Tanimoto R, Watanabe M, Murata H, Than SS, Kurose K, Kashiwakura Y, Ochiai K, Nasu Y, Kumon H, et al. : Overexpression of REIC/Dkk-3 in normal fibroblasts suppresses tumor growth via induction of interleukin-7. J Biol Chem (2005) 284, 14236-14244. 15) Watanabe M, Kashiwakura Y, Huang P, Ochiai K, Futami J, Li SA, Takaoka M, Nasu Y, Sakaguchi M, Huh NH, Kumon H : Immunological aspects of REIC/Dkk-3 in monocyte differentiation and tumor regression. Int J Oncol (2009) 34, 657-663. 16) Edamura K, Nasu Y, Takaishi M, Kobayashi T, Abarzua F, Sakaguchi M, Kashiwakura Y, Ebara S, Saika T, Watanabe M, Huh NH, Kumon H : Adenovirus-mediated REIC/Dkk-3 gene transfer inhibits tumor growth and metastasis in an orthotopic prostate cancer model. Cancer Gene Ther (2007) 14, 765-772.
Sort Key 7
Title Alternative Induction therapy followed by surgery for non small-cell lung cancer
FullText URL 126_103.pdf
Author Toyooka, Shinichi|
Keywords 非小細胞肺癌 導入療法 放射線化学療法 外科切除
Note 総説 (Reviews)
Publication Title 岡山医学会雑誌
Published Date 2014-08-01
Volume volume126
Issue issue2
Publisher 岡山医学会
Publisher Alternative Okayama Medical Association
Start Page 103
End Page 107
ISSN 0030-1558
NCID AN00032489
Content Type Journal Article
language 日本語
Copyright Holders Copyright (c) 2014 岡山医学会
File Version publisher
Refereed True
DOI 10.4044/joma.126.103
NAID 130004685260
Eprints Journal Name joma
References 1) Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M, et al. : A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst (1994) 86, 673-680. 2) Rosell R, Gómez-Codina J, Camps C, Maestre J, Padille J, Cantó A, Mate JL, Li S, Roig J, Olazábal A, et al. : A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med (1994) 330, 153-158. 3) Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT 3rd, Weick JK, Lonchyna VA, Presant CA, McKenna RJ, Gandara DR, et al. : Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages ⅢA (N2) and ⅢB non-small-cell lung cancer : mature results of Southwest Oncology Group phaseⅡstudy 8805. J Clin Oncol (1995) 13, 1880-1892. 4) Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, et al. : Radiotherapy plus chemotherapy with or without surgical resection for stageⅢnon-small-cell lung cancer : a phase Ⅲrandomised controlled trial. Lancet (2009) 374, 379-386. 5) van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, Tjan-Heijnen VC, Biesma B, Debruyne C, van Zandwijk N, Splinter TA, Giaccone G ; European Organisation for Research and Treatment of Cancer-Lung Cancer Group : Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage ⅢA-N2 non-small-cell lung cancer. J Natl Cancer Inst (2007) 99, 442-450. 6) Date H, Kiura K, Ueoka H, Tabata M, Aoe M, Andou A, Shibayama T, Shimizu N : Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N(2) non-small cell lung cancer. Br J Cancer (2002) 86, 530-533. 7) Katayama H, Ueoka H, Kiura K, Tabata M, Kozuki T, Tanimoto M, Fujiwara T, Tanaka N, Date H, Aoe M, Shimizu N, Takemoto M, et al. : Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer. Br J Cancer (2004) 90, 979-984. 8) Toyooka S, Kiura K, Takemoto M, Oto T, Takigawa N, Fujiwara T, Miyoshi S, Date H : Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg (2012) 14, 565-569. 9) Toyooka S, Kiura K, Shien K, Katsui K, Hotta K, Kanazawa S, Date H, Miyoshi S : Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg (2012) 15, 954-960. 10) Shien K, Toyooka S, Kiura K, Matsuo K, Soh J, Yamane M, Oto T, Takemoto M, Date H, Miyoshi S : Induction chemoradiotherapy followed by surgical resection for clinical T3 or T4 locally advanced non-small cell lung cancer. Ann Surg Oncol (2012) 19, 2685-2692. 11) Felip E, Rosell R, Maestre JA, Rodríguez-Paniagua JM, Morán T, Astudillo J, Alonso G, Borro JM, González-Larriba JL, Torres A, Camps C, Guijarro R,et al. ; Spanish Lung Cancer Group : Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol (2010) 28, 3138-3145. 12) NSCLC Meta-analysis Collaborative Group : Preoperative chemotherapy for non-small cell lung cancer : a systematic review and meta-analysis of individual participant data. Lancet (2014) 383, 1561-1571. 13) Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D : Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas : long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol (2007) 25, 313-318. 14) Kunitoh H, Kato H, Tsuboi M, Shibata T, Asamura H, Ichinose Y, Katakami N, Nagai K, Mitsudomi T, Matsumura A, Nakagawa K, Tada H, et al. ; Japan Clinical Oncology Group : PhaseⅡtrial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers : report of Japan Clinical Oncology Group trial 9806. J Clin Oncol (2008) 26, 644-649. 15) Toyooka S, Soh J, Oto T, Miyoshi S : Bronchoplasty to adjust mismatches in the proximal and distal bronchial stumps during bronchial sleeve resection of the left lower lobe and lingular division. Eur J Cardiothorac Surg (2013) 43, 182-183. 16) Toyooka S, Soh J, Shien K, Sugimoto S, Yamane M, Oto T, Date H, Miyoshi S : Sacrificing the pulmonary arterial branch to the spared lobe is a risk factor of bronchopleural fistula in sleeve lobectomy after chemoradiotherapy. Eur J Cardiothorac Surg (2013) 43, 568-572. 17) Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, et al. : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 350, 2129-2139. 18) Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, et al. : EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy. Science (2004) 304, 1497-1500. 19) Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, et al. : Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 448, 561-566. 20) Cappuzzo F, Bemis L, Varella-Garcia M : HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med (2006) 354, 2619-2621. 21) Gautschi O, Pauli C, Strobel K, Hirschmann A, Printzen G, Aebi S, Diebold J : A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol (2012) 7, e23-24. 22) Shigematsu H, Gazdar AF : Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer (2006) 118, 257-262. 23) Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, Iwakawa R, Ogiwara H, et al. : KIF5B-RET fusions in lung adenocarcinoma. Nat Med (2012) 18, 375-377. 24) Hishida T, Nagai K, Mitsudomi T, Yokoi K, Kondo H, Horinouchi H, Akiyama H, Nagayasu T, Tsuboi M ; Japan Clinical Oncology G : Salvage surgery for advanced non-small cell lung cancer after response to gefitinib. J Thorac Cardiovasc Surg (2010) 140, e69-71. 25) Jaklitsch MT, Herndon JE 2nd, DeCamp MM Jr, Richards WG, Kumar P, Krasna MJ, Green MR, Sugarbaker DJ : Nodal downstaging predicts survival following induction chemotherapy for stage ⅢA (N2) non-small cell lung cancer in CALGB protocol #8935. J Surg Oncol (2006) 94, 599-606. 26) Shintani Y, Okimura A, Sato K, Nakagiri T, Kadota Y, Inoue M, Sawabata N, Minami M, Ikeda N, Kawahara K, Matsumoto T, Matsuura N, et al. : Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann Thorac Surg (2011) 92, 1794-1804 ; discussion 1804. 27) Shien K, Toyooka S, Ichimura K, Soh J, Furukawa M, Maki Y, Muraoka T, Tanaka N, Ueno T, Asano H, Tsukuda K, Yamane M, et al. : Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer (2012) 77, 162-167.
JaLCDOI 10.18926/AMO/49253
FullText URL 67_1_19.pdf
Author Furukawa, Masashi| Soh, Junichi| Yamamoto, Hiromasa| Ichimura, Kouichi| Shien, Kazuhiko| Maki, Yuho| Muraoka, Takayuki| Tanaka, Norimitsu| Ueno, Tsuyoshi| Asano, Hiroaki| Tsukuda, Kazunori| Toyooka, Shinichi| Miyoshi, Shinichiro|
Abstract Nuclear factor of κ-light polypeptide gene enhancer in B cells inhibitor α (NFKBIA), which is a tumor suppressor gene, was found to be silenced in lung adenocarcinomas. We examined NFKBIA expression, mutations in the EGFR and K-ras genes, and EML4-ALK fusion in 101 resected lung adenocarcinoma samples from never-smokers. NFKBIA expression was evaluated using immunohistochemistry. NFKBIA expression was negative in 16 of the 101 samples (15.8%). EGFR and K-ras mutations and EML4-ALK fusion were detected in 61 (60.5%), 1 (1.0%), and 2 (2.0%) of the 101 samples, respectively, in a completely mutually exclusive manner. Negative NFKBIA expression was observed significantly more frequently among the tumors with none of the three genetic alterations compared to those with such alterations (p=0.009). In addition, negative NFKBIA expression was significantly more frequent among the EGFR-wild type samples compared to the EGFR-mutant samples (p=0.013). In conclusion, NFKBIA expression was silenced in adenocarcinomas without EGFR/K-ras mutations or EML4-ALK fusion, suggesting that the silencing of NFKBIA may play an important role in the carcinogenesis of adenocarcinomas independent of EGFR/K-ras mutations or EML4-ALK fusion.
Keywords never-smoker lung cancer adenocarcinoma nuclear factor of κ-light polypeptide gene enhancer in B cells inhibitor α epidermal growth factor receptor
Amo Type Original Article
Published Date 2013-02
Publication Title Acta Medica Okayama
Volume volume67
Issue issue1
Publisher Okayama University Medical School
Start Page 19
End Page 24
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2013 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 23439505
Web of Sience KeyUT 000316829900003
Related Url http://ousar.lib.okayama-u.ac.jp/metadata/52534
Author Kubo, Takafumi| Toyooka, Shinichi| Miyoshi, Shinichiro|
Published Date 2012-12-03
Publication Title 岡山医学会雑誌
Volume volume124
Issue issue3
Content Type Journal Article
Author Shien, Kazuhiko| Toyooka, Shinichi| Ichimura, Kouichi| Soh, Junichi| Furukawa, Masashi| Maki, Yuho| Muraoka, Takayuki| Tanaka, Norimitsu| Ueno, Tsuyoshi| Asano, Hiroaki| Tsukuda, Kazunori| Yamane, Masaomi| Oto, Takahiro| Kiura, Katsuyuki| Miyoshi, Shinichiro|
Published Date 2012-07
Publication Title Lung Cancer
Volume volume77
Issue issue1
Content Type Journal Article
Author Ueno, Tsuyoshi| Tsukuda, Kazunori| Toyooka, Shinichi| Ando, Midori| Takaoka, Munenori| Soh, Junichi| Asano, Hiroaki| Maki, Yuho| Muraoka, Takayuki| Tanaka, Norimitsu| Shien, Kazuhiko| Furukawa, Masashi| Yamatsuji, Tomoki| Kiura, Katsuyuki| Naomoto, Yoshio| Miyoshi, Shinichiro|
Published Date 2012-04
Publication Title Lung Cancer
Volume volume76
Issue issue1
Content Type Journal Article
Author Tanaka, Norimitsu| Toyooka, Shinichi| Soh, Junichi| Kubo, Takafumi| Yamamoto, Hiromasa| Maki, Yuho| Muraoka, Takayuki| Shien, Kazuhiko| Furukawa, Masashi| Ueno, Tsuyoshi| Asano, Hiroaki| Tsukuda, Kazunori| Aoe, Keisuke| Miyoshi, Shinichiro|
Published Date 2012-04
Publication Title Lung Cancer
Volume volume76
Issue issue1
Content Type Journal Article
Author Suehisa, Hiroshi| Toyooka, Shinichi| Hotta, Katsuyuki| Uchida, Akiko| Soh, Junichi| Fujiwara, Yoshiro| Matsuo, Keitaro| Ouchida, Mamoru| Takata, Minoru| Kiura, Katsuyuki| Date, Hiroshi|
Published Date 2008-12-01
Publication Title 岡山医学会雑誌
Volume volume120
Issue issue3
Content Type Journal Article
Author Toyooka, Shinichi| Date, Hiroshi|
Published Date 2008-05-01
Publication Title 岡山医学会雑誌
Volume volume120
Issue issue1
Content Type Journal Article
Author Sugimoto, Seiichiro| Date, Hiroshi| Sugimoto, Ryujiro| Yamane, Masaomi| Toyooka, Shinichi| Oto, Takahiro| Aoe, Motoi| Sano, Yoshifumi|
Published Date 2007-09-03
Publication Title 岡山医学会雑誌
Volume volume119
Issue issue2
Content Type Journal Article
Author 豊岡 伸一|
Published Date 2001-03-25
Publication Title
Content Type Thesis or Dissertation